Delving into the Latest Updates on Indantadol Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Indantadol

+ [14]

Target

MAO-A x MAO-B x NMDA receptor

Mechanism

MAO-A inhibitors(Monoamine oxidase A inhibitors), MAO-B inhibitors(Monoamine oxidase B inhibitors), NMDA receptor antagonists(Glutamate [NMDA] receptor antagonists)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseRespiratory Diseases

Active Indication-

Inactive Indication

CoughDiabetic peripheral neuropathic painNeuralgia+ [2]

Originator Organization

CHIESI Farmaceutici SpA

Active Organization-

Inactive Organization

Vernalis (R&D) Ltd.Cita NeuroPharmaceuticals, Inc.

Ligand UK Ltd.

+ [1]

Drug Highest PhaseDiscontinuedPhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC11H14N2O

InChIKeyMNLULKBKWKTZPE-UHFFFAOYSA-N

CAS Registry202844-10-8

View All Structures (2)

The investigators hypothesise that cough reflex hypersensitivity, demonstrated in chronic cough patients, is due to a phenomenon known as central sensitisation. Central sensitisation is a hyper-excitability of the sensory nerves as they join the central nervous system, and is believed to be mediated by the N-Methyl-D-Aspartate (NMDA) receptor[1-3].

Start Date01 Oct 2009

Sponsor / Collaborator

Vernalis (R&D) Ltd.

[+1]

EUCTR2009-011525-13-GB / Not yet recruitingNot Applicable

Phase II Open-label Pilot Study of V3381, a Novel N-Methyl-D-Aspartate Receptor Antagonist, in Chronic Cough Patients attending a Specialist Clinic - Phase II Open-Label Pilot Study of V3381 in Chronic Cough

Start Date28 Aug 2009

Sponsor / Collaborator

Vernalis (R&D) Ltd.

EUCTR2008-007978-38-GB / Not yet recruitingNot Applicable

A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Parallel Group Study of the Safety, Tolerability and Efficacy of V3381 for Up to 13 Weeks in Patients with Diabetic Peripheral Neuropathic Pain (DPNP) - IN-STEP (Indantadol - Safety Tolerability and Efficacy in Pain)

Start Date12 Feb 2009

Sponsor / Collaborator-

100 Clinical Results associated with Indantadol Hydrochloride

Login to view more data

100 Translational Medicine associated with Indantadol Hydrochloride

Login to view more data

100 Patents (Medical) associated with Indantadol Hydrochloride

Login to view more data

813

Literatures (Medical) associated with Indantadol Hydrochloride

23 Feb 2023·Blood

Aging drives Tet2 +/− clonal hematopoiesis via IL-1 signaling

Article

Author: Kovtonyuk, Larisa V. ; Gonullu, Nagihan G. ; Manz, Markus G. ; Fullin, Jonas ; Caiado, Francisco ; Boettcher, Steffen

AbstractClonal hematopoiesis of indeterminate potential (CHIP), also referred to as aging-related clonal hematopoiesis, is defined as an asymptomatic clonal expansion of mutant mature hematopoietic cells in ≥4% of blood leukocytes. CHIP associates with advanced age and increased risk for hematological malignancy, cardiovascular disease, and all-cause mortality. Loss-of-function somatic mutations in TET2 are frequent drivers of CHIP. However, the contribution of aging-associated cooperating cell-extrinsic drivers, like inflammation, remains underexplored. Using bone marrow (BM) transplantation and newly developed genetic mosaicism (HSC-SCL-Cre-ERT; Tet2+/flox; R26+/tm6[CAG-ZsGreen1]Hze) mouse models of Tet2+/−driven CHIP, we observed an association between increased Tet2+/− clonal expansion and higher BM levels of the inflammatory cytokine interleukin-1 (IL-1) upon aging. Administration of IL-1 to mice carrying CHIP led to an IL-1 receptor 1 (IL-1R1)–dependent expansion of Tet2+/− hematopoietic stem and progenitor cells (HSPCs) and mature blood cells. This expansion was caused by increased Tet2+/− HSPC cell cycle progression, increased multilineage differentiation, and higher repopulation capacity compared with their wild-type counterparts. In agreement, IL-1α–treated Tet2+/− hematopoietic stem cells showed increased DNA replication and repair transcriptomic signatures and reduced susceptibility to IL-1α–mediated downregulation of self-renewal genes. More important, genetic deletion of IL-1R1 in Tet2+/− HPSCs or pharmacologic inhibition of IL-1 signaling impaired Tet2+/− clonal expansion, establishing the IL-1 pathway as a relevant and therapeutically targetable driver of Tet2+/− CHIP progression during aging.

01 Sep 2022·Annals of the Rheumatic Diseases

Response to: ‘More evidences on which biologic and which pathway is key in severe-critical COVID-19 pneumonia’ by Ferraccioli

Article

Author: Ciceri, Fabio ; Dagna, Lorenzo ; De Luca, Giacomo ; Della-Torre, Emanuel ; Campochiaro, Corrado ; Cavalli, Giulio ; Zangrillo, Alberto

A polemic in response to Ferraccioli et al is given.This article describes the open-label trials with sarilumab, tocilizumab, anakinra and mavrilimumab in patients with severe hyperinflamed COVID-19.In this article the IL-1 or GM-CSF seems a more promising approach since upstream blockade of the inflammatory cascade may allow a better control of cytokine storm-induced organ damage with a better safety profile are discussed.

01 Feb 2022·Nature Reviews RheumatologyQ1 · MEDICINE

DRESS linked to HLA alleles

Q1 · MEDICINE

Article

Author: Onuora, Sarah

A review.A case-control study suggest that delayed hypersensitivity reactions to IL-1 or IL-6 inhibitors are strongly associated with a common HLA class II haplotype.The researchers suggest that HLA testing should be considered as part of pre-prescription risk assessment, and that vigilance for DRESS is needed during treatment with IL-1 and IL-6 inhibitors.

100 Deals associated with Indantadol Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Indantadol Hydrochloride	-	DB12664

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cough	Phase 2	GB	Ligand UK Ltd.	01 Oct 2009
Refractory chronic cough	Phase 2	GB	Vernalis (R&D) Ltd.	18 Jun 2009
Unexplained chronic cough	Phase 2	GB	Vernalis (R&D) Ltd.	18 Jun 2009
Diabetic peripheral neuropathic pain	Phase 2	CA	Cita NeuroPharmaceuticals, Inc.	01 Jun 2006
Diabetic peripheral neuropathic pain	Phase 2	US	Vernalis (R&D) Ltd.	01 Jun 2006
Diabetic peripheral neuropathic pain	Phase 2	US	Cita NeuroPharmaceuticals, Inc.	01 Jun 2006
Diabetic peripheral neuropathic pain	Phase 2	CA	Vernalis (R&D) Ltd.	01 Jun 2006
Neuralgia	Phase 2	-	CHIESI Farmaceutici SpA	-